| 6.13 0.07 (1.16%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.84  |
1-year : | 9.16 |
| Resists | First : | 6.71 |
Second : | 7.84 |
| Pivot price | 4.52 |
|||
| Supports | First : | 4.66 |
Second : | 3.4 |
| MAs | MA(5) : | 5.51 |
MA(20) : | 4.33 |
| MA(100) : | 3.23 |
MA(250) : | 1.87 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 88.3 |
D(3) : | 81 |
| RSI | RSI(14): 75.3 |
|||
| 52-week | High : | 6.71 | Low : | 0.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMAB ] has closed below upper band by 4.4%. Bollinger Bands are 131.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.73 - 6.76 | 6.76 - 6.79 |
| Low: | 5.93 - 5.96 | 5.96 - 5.99 |
| Close: | 6.09 - 6.13 | 6.13 - 6.18 |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Thu, 16 Oct 2025
I-Mab To Present Updated Givastomig Data In Gastric Cancer At Major Oncology Conference Next Week - RTTNews
Tue, 14 Oct 2025
I-Mab Biopharma Stock: Caution Warranted After Huge Surge (NASDAQ:IMAB) - Seeking Alpha
Tue, 14 Oct 2025
BTIG Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Tue, 14 Oct 2025
I-Mab to Present Updated Phase 1 Data on Givastomig at AACR-NCI-EORTC Conference 2025 - Quiver Quantitative
Tue, 14 Oct 2025
I-Mab to Present Short-Talk on Updated Givastomig - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 115 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 20 (%) |
| Shares Short | 2,630 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.4 % |
| Return on Equity (ttm) | -18.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 44 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -12.02 |
| PEG Ratio | 0 |
| Price to Book value | 2.55 |
| Price to Sales | 0 |
| Price to Cash Flow | 16.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|